<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543982</url>
  </required_header>
  <id_info>
    <org_study_id>UAS1RPD-160001-PRVH</org_study_id>
    <nct_id>NCT03543982</nct_id>
  </id_info>
  <brief_title>Effects of Oral Probiotic Product on Vaginal Microbial Community and Parameters of Vaginal Health</brief_title>
  <official_title>An Open-label, Pilot Study to Assess the Effects of an Oral Probiotic Product on the Vaginal Microbial Community and on Parameters of Vaginal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UAS Labs LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UAS Labs LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of an oral probiotic product on&#xD;
      the vaginal microbiome and on parameters of vaginal health. Eligible subjects will utilize&#xD;
      the investigational product as directed for a period of 28 days. The vaginal microbial&#xD;
      community and parameters of vaginal health will be measured at baseline and after 14 and 28&#xD;
      days of supplementation. A follow-up post-supplementation visit will be conducted on Day 42.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Actual">March 18, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in vaginal microbial community, via next generation sequencing.</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vaginal microbial community, via next generation sequencing.</measure>
    <time_frame>Day 14 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vaginal pH.</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Nugent Score (Scale of 0 to 10).</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters of well-being, via Vulvovaginal Symptom Questionnaire.</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by routine chemistry and hematology, and the monitoring of adverse events.</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance as assessed by capsule counts of the returned IP.</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Colonization of the vaginal microbiome.</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Colonization of the GI microbiome.</measure>
    <time_frame>Day 14, 28 and 42</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Vaginal Health</condition>
  <arm_group>
    <arm_group_label>Oral probiotic product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral probiotic product</intervention_name>
    <description>Once per day (QD), 28 days</description>
    <arm_group_label>Oral probiotic product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy women aged 18-50 years.&#xD;
&#xD;
          2. Body mass index 18.5 - 34.9 kg/m2 (inclusive).&#xD;
&#xD;
          3. Have childbearing potential [i.e. not surgically sterile or post-menopausal (greater&#xD;
             than one year since last menses)].&#xD;
&#xD;
          4. Non-smoker, or ex-smoker â‰¥6 months.&#xD;
&#xD;
          5. Nugent score of 4-6 or pH &gt;4.5&#xD;
&#xD;
          6. Agrees to maintain current level of physical activity and dietary habits throughout&#xD;
             the trial period.&#xD;
&#xD;
          7. Agrees to discontinue use of probiotic supplements (oral or vaginal), as well as food&#xD;
             supplemented with probiotics or prebiotics.&#xD;
&#xD;
          8. Willing and able to provide written informed consent.&#xD;
&#xD;
          9. Agrees to provide fecal samples during the trial period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to any ingredient in the study product.&#xD;
&#xD;
          2. Pregnancy or planning pregnancy.&#xD;
&#xD;
          3. Lactation or breast feeding.&#xD;
&#xD;
          4. Irregular menstrual cycles.&#xD;
&#xD;
          5. Use of contraceptives that contain spermicidal agents.&#xD;
&#xD;
          6. Use of an intrauterine device (IUD).&#xD;
&#xD;
          7. Use of hormonal therapy through cervical cap.&#xD;
&#xD;
          8. Use of douching devices.&#xD;
&#xD;
          9. Any major trauma or surgical event within the 3 months prior to screening.&#xD;
&#xD;
         10. Individuals undergoing therapies to prevent any recurrent infections.&#xD;
&#xD;
         11. Allergy to any antibiotic that may be prescribed as a rescue remedy during the study.&#xD;
&#xD;
         12. Use of prescription drugs (other than birth control) within 1 month prior to Visit 1.&#xD;
&#xD;
         13. Use of antibiotics within 2 months prior to Visit 1.&#xD;
&#xD;
         14. History of blood clotting disorders or use of coagulation-inhibiting drugs (e.g.&#xD;
             warfarin)&#xD;
&#xD;
         15. Presence of systemic diseases or immunodeficiencies&#xD;
&#xD;
         16. Abdominal or gastrointestinal surgery within the previous 12 months.&#xD;
&#xD;
         17. Recent gastrointestinal food-borne illness (within 1 month prior to Visit 1)&#xD;
&#xD;
         18. History of cancer (excluding non-melanoma skin cancer and basal cell carcinoma) in the&#xD;
             past 5 years&#xD;
&#xD;
         19. Abnormal laboratory test results of clinical significance&#xD;
&#xD;
         20. Presence or history (past 6 months) of alcohol or drug abuse&#xD;
&#xD;
         21. Subject is unwilling or unable to abide by the requirements of the protocol&#xD;
&#xD;
         22. Any condition that would interfere with the subject's ability to comply with study&#xD;
             instructions, might confound the interpretation of the study, or put the subject at&#xD;
             risk&#xD;
&#xD;
         23. Subject has taken an investigational health product or has participated in a research&#xD;
             study within 30 days prior to first study visit&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nutrasource</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1G 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

